Literature DB >> 22878691

Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.

Isabel Spriet, Veerle Grootaert, Geert Meyfroidt, Yves Debaveye, Ludo Willems.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22878691     DOI： 10.1007/s00228-012-1365-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  10 in total

1.  Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato; Akiko Yamane; Masatoshi Sakurai; Sumiko Kohashi; Taku Kikuchi; Yukako Ono; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2012-03-30       Impact factor: 2.490

Review 2.  Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

Authors:  Aline H Saad; Daryl D DePestel; Peggy L Carver
Journal:  Pharmacotherapy       Date:  2006-12       Impact factor: 4.705

3.  The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.

Authors:  Motohiro Kato; Koji Chiba; Akihiro Hisaka; Michi Ishigami; Makoto Kayama; Naomi Mizuno; Yoshinori Nagata; Susumu Takakuwa; Yuko Tsukamoto; Kaoru Ueda; Hiroyuki Kusuhara; Kiyomi Ito; Yuichi Sugiyama
Journal:  Drug Metab Pharmacokinet       Date:  2003       Impact factor: 3.614

4.  Highly activated oral bioavailability of tacrolimus on coadministration of oral voriconazole.

Authors:  Y Inoue; T Saito; M Takimoto; K Ogawa; Y Shibuya; Y Suzuki; M Kato; M Takahashi; I Miura; Y Hatta; J Takeuchi
Journal:  Int J Clin Pharmacol Ther       Date:  2011-04       Impact factor: 1.366

5.  Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.

Authors:  Shimin Zhang; Venkateswaran C Pillai; Sripal Reddy Mada; Steve Strom; Raman Venkataramanan
Journal:  Xenobiotica       Date:  2011-11-22       Impact factor: 1.908

6.  Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction.

Authors:  Mordechai R Kramer; Anat Amital; Leonardo Fuks; David Shitrit
Journal:  Clin Transplant       Date:  2010-12-16       Impact factor: 2.863

7.  Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.

Authors:  L C Floren; I Bekersky; L Z Benet; Q Mekki; D Dressler; J W Lee; J P Roberts; M F Hebert
Journal:  Clin Pharmacol Ther       Date:  1997-07       Impact factor: 6.875

8.  Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers.

Authors:  M F Hebert; R M Fisher; C L Marsh; D Dressler; I Bekersky
Journal:  J Clin Pharmacol       Date:  1999-01       Impact factor: 3.126

9.  Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.

Authors:  Raman Venkataramanan; Shimin Zang; Timothy Gayowski; Nina Singh
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Voriconazole does not affect the steady-state pharmacokinetics of digoxin.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335
  10 in total
  2 in total

1.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

Review 2.  Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?

Authors:  Umberto Maggiore; Alessandra Palmisano; Sebastiano Buti; Giulia Claire Giudice; Dario Cattaneo; Nicola Giuliani; Enrico Fiaccadori; Ilaria Gandolfini; Paolo Cravedi
Journal:  Transpl Int       Date:  2021-10-28       Impact factor: 3.842
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.